A prediction model of survival for patients with bone metastasis from
                    uterine corpus cancer

Takeshita, Sho; Todo, Yukiharu; Matsumiya, Hiroko; Okamoto, Kazuhira; Yamashiro, Katsushige; Kato, Hidenori

doi:10.1093/jjco/hyw120

Cited by 9 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uccella et al [22] also pointed out that the incidence of osseous dissemination in EC was less than 1% according to literature review. While in Takeshita's cohort study [28], the incidence rate was up to 3.1%. The difference of sources of patients admitted to research centers might attribute to this distinction.…”

Section: Discussionmentioning

confidence: 88%

Bone Metastases of Endometrial Carcinoma Treated by Surgery: Report on 13 Patients and Review of The Medical Literature

Wang

Dai

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: The aim of this study was to describe the clinicopathological features of EC patients with bone metastases treated with surgery and to systematically review the literature. Methods: We performed a retrospective study to include patients with bone metastases of EC at Peking University People’s Hospital during 2000 to 2019. Clinicopathological features and survival outcomes were collected.Results: Among the 1662 patients with EC, 14 (0.84%) were identified with bone metastases, and all were treated surgically. 13 cases were analyzed. Four had bone metastases when diagnosed; and the remaining 9 cases had bone metastases when first relapsed with the median time to recurrence of 13 months (range, 5-144). The median age of the 13 patients was 58 years old (range, 45-76). Twelve were endometrioid carcinoma. The majority sites of bone metastases were pelvis, followed by the spine. The median overall survival (OS) was 57 months. We further combined the 13 patients with another 24 cases identified from literature research. There was no significant difference in clinicopathological characteristics between the patients with bone metastases when diagnosed and when first relapsed. The median OS was numerically longer for patients with bone metastases when diagnosed than when first relapsed (57 vs. 36 months, P=0.084). The median OS was significantly longer in patients with endometrioid carcinoma than in those with type II carcinoma (57 vs. 4 months, P=0.003). Conclusions: Patients with bone metastases of EC might benefit from comprehensive treatment based on surgery, as symptoms can be palliated and survival can be extended probably.

show abstract

Section: Discussionmentioning

confidence: 88%

Bone Metastases of Endometrial Carcinoma Treated by Surgery: Report on 13 Patients and Review of The Medical Literature

Wang

Dai

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The median patient age at the time of diagnosis of bone metastases ranged from 47.5 [ 26 ] to 75.5 [ 29 ]. A postmenopausal status was reported in 5/12 studies, while the others did not specify the menopausal status [ 23 , 24 , 29 , 30 , 31 ]. At the time of EC diagnosis, most patients had a FIGO Stage III–IV with Grade II–III.…”

Section: Resultsmentioning

confidence: 99%

“…EC bone metastases were mostly diagnosed with PET/CT or CT alone, followed by MRI and X-ray [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. The bone metastases-free interval ranged from 6 months [ 23 ] to 19.5 months [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

“…Ovarian cancer Deng et al 2018 [18] NA NA NA Sehouli et al 2013 [19] NA NA NA Zhang et al 2013 [20] CD NA NA NA Zhang et al 2019 [21] NA NA NA Endometrial cancer Guo et al 2020 [22] NA NA NA Hong et al 2021 [23] NA NA NA Kimyon et al 2016 [24] NA NA NA Li et al 2020 [25] NA NA NA Liu et al 2020 [26] NA NA NA Mao et al 2020 [27] NA NA NA McEachron et al 2020 [28] NA NA NA Ouldamer et al 2019 [29] NA NA NA Takeshita et al 2016 [30] NA NA NA Uccella et al 2013 [31] NA NA NA Yoon et al 2014 [32] NA NA NA Uterine sarcoma Bartosh et al 2017 [33] NA NA NA Tirumani et al 2014 [34] NA NA NA Vulvar cancer Prieske et al 2016 [35] NA NA NA Cervical cancer Kanayama et al 2015 [36] NA NA NA Kocaer et al 2018 [37] NA NA NA Lin et al 2018 [38] NA NA NA Makino et al 2016 [39] NA NA NA Manders et al 2018 [40] NA NA NA Matsumiya et al 2016 [41] NA NA NA Nartthanarung et al 2014 [42] NA NA NA Sethi et al 2019 [43] NA NA NA Yin et al 2019 [44] NA NA NA Yoon et al 2013 [45] NA NA NA Zhang et al 2018 [46] NA NA NA Zhang et al 2020 [47] NA NA NA Zhou et al 2020 [48] NA NA NA Acknowledgments: This work was supported by IRCCS Istituto Ortopedico Rizzoli (Ricerca Corrente).…”

Section: Conflicts Of Interestmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Characteristics, Treatment Modalities, and Potential Contributing and Prognostic Factors in Patients with Bone Metastases from Gynecological Cancers: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

The purpose of this study is to review the clinical characteristics, treatment modalities, and potential contributing and prognostic factors of bone metastases from gynecological cancers (GCs). A systematic literature search on PubMed, Scopus, Web of Science Core Collection and Cochrane Central Register of Controlled Trials databases was conducted. Thirty-one studies, all retrospective, were included in this review, for a total of 2880 patients with GC bone metastases. Primary tumors leading to bone metastases included endometrial cancer (EC), cervical cancer (CC), ovarian cancer (OC), uterine sarcoma (US) and vulvar cancer (VuC), mainly with an International Federation of Gynecology and Obstetrics (FIGO) Stage of III and IV. The main bone metastatic lesion site was the vertebral column, followed by the pelvic bone and lower extremity bones. The median survival rate after bone metastases diagnosis ranged from 3.0 to 45 months. The most frequent treatments were palliative and included radiotherapy and chemotherapy, followed by surgery. The findings of this review give a first dataset for a greater understanding of GC bone metastases that could help clinicians move toward a more “personalized” and thus more effective patient management.

show abstract

“…[ 4 , 5 ] The occurrence of BM in EC patients means a poor prognosis, with a 5-year survival rate of only 8.7%. [ 6 , 7 ] Hence, it is of great significance to identify risk factors and conditions for BM in EC patients as soon as possible.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic factors, and two nomograms for endometrial cancer patients with bone metastasis

et al. 2021

View full text Add to dashboard Cite

Patients with endometrial cancer (EC) who develop bone metastasis (BM) always imply a poorer prognosis. However, reliable predictive models associated with BM from EC are currently limited. We retrospectively analyzed data on 54,077 patients diagnosed with primary EC in the Surveillance, Epidemiology, and End Results database. Multivariate logistic regression analysis was used to determine independent predictors of BM from EC. Univariate and multivariate Cox regression analyses were used to determine independent prognostic factors for EC with BM. Based on independent predictors and prognostic factors, we constructed a diagnostic nomogram and prognostic nomogram separately. Besides, calibration curves, receiver operating characteristic curves, and decision curve analysis were used to evaluate the models. A total of 54,077 patients with EC from the Surveillance, Epidemiology, and End Results database were included in this study, 364 of whom had BM. Multivariate analysis in the logistic model showed that lung metastasis, liver metastasis, brain metastasis, N stage, T stage, histologic grade, and race were risk factors for BM from EC. Multivariate analysis in the Cox model showed that liver metastasis, brain metastasis, chemotherapy, surgery, and histologic type had a significant effect on overall survival. Moreover, the receiver operating characteristic curve, calibration curve, and decision curve analysis indicated the good performance of both diagnostic and prognostic nomograms. Two clinical prediction model was constructed and validated to predict individual risk and overall survival for EC with BM, respectively. Diagnostic nomogram and prognostic nomogram are complementary, improving the clinician's ability to assess the patient's prognosis and enhancing prognosis-based decision making.

show abstract

A prediction model of survival for patients with bone metastasis from uterine corpus cancer

Abstract: This scoring system can be used to determine the optimal treatment for patients with bone metastasis from endometrial cancer.

Cited by 9 publications

References 15 publications

Bone Metastases of Endometrial Carcinoma Treated by Surgery: Report on 13 Patients and Review of The Medical Literature

Bone Metastases of Endometrial Carcinoma Treated by Surgery: Report on 13 Patients and Review of The Medical Literature

Clinical Characteristics, Treatment Modalities, and Potential Contributing and Prognostic Factors in Patients with Bone Metastases from Gynecological Cancers: A Systematic Review

Diagnostic and prognostic factors, and two nomograms for endometrial cancer patients with bone metastasis

Contact Info

Product

Resources

About